Navigation Links
Watson Confirms Viagra® Patent Challenge
Date:6/2/2011

PARSIPPANY, N.J., June 2, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Sildenafil Citrate Tablets, 25, 50 and 100 mg. Watson's Sildenafil Citrate tablets are a generic version of Pfizer Inc.'s Viagra®, which is indicated for the treatment of erectile dysfunction (ED).

Pfizer filed suit against Watson on June 1, 2011 in the United States District Court for the Southern District of New York seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 6,469,012.  Pfizer's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until November 6, 2013 or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

For the twelve months ending April 30, 2011, Viagra® had total U.S. sales of just over $1 billion, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspectiv
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Amar Singh , Chief Business Officer and Executive Vice President. ... on July 30. "Sorrento is deeply saddened and ... Our immediate thoughts go to Amar,s family and friends," said ... Officer. Mr. Singh joined Sorrento in January ...
(Date:7/31/2014)... (NYSE: RMD ) today announced results for its ... 2014.  Revenue for the quarter was $415.2 million, flat compared ... decrease on a constant currency basis). Net income was $87.7 ... ended June 30, 2013. Diluted earnings per share for the ... the quarter ended June 30, 2013.  The ...
(Date:7/31/2014)... July 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... developments for the quarter ended June 30, 2014. ... 30, 2014 Revenue Total revenue for the quarter ended ... for the quarter ended June 30, 2013 primarily due to ... Total revenue for the six months ended ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
(Date:8/1/2014)... According to Forrester Research, more than 90 percent of ... of information, and thanks to the launching of DCInsurers Agent ... resources on insurance specifically for the state of Colorado can ... step in the growth of our business,” Doug King, owner/agent ... Insurance Resources office. “We recognize that the web is how ...
(Date:8/1/2014)... KY (PRWEB) August 01, 2014 Frontier ... Health Resources and Services Administration’s Advanced Education Nursing ... and will provide direct support to 280 students over ... the AENT Program is to increase the number of ... providers and/or nursing faculty to address the nurse faculty ...
(Date:8/1/2014)... and doctors at the Institute of Bioengineering and ... Cancer Centre Singapore (NCCS) have co-developed the first ... survival outcomes in kidney cancer patients. This breakthrough ... the world,s top urology journal. , According ... "By combining our expertise in molecular diagnostics and ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... Utah (PRWEB) August 01, 2014 This ... MonaVie, who completes its 500th week of paying commissions ... the company was founded in January 2005 total $1,405,954,677.06. ... throughout the world. The company pays commissions in 18 ... ILS, JPY, MYR, MXN, NZD, PLN, USD, SGD, KRW, ...
Breaking Medicine News(10 mins):Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2
... between Elsevier and Diabetes India. The partnership would be ... Diabetes Research & Metabolic Syndrome in June 2006. // ... relationship between diabetes and metabolic syndrome with special reference ... centered approach in treatment of the disorder. ,Diabetes India ...
... breakthrough, scientists have successfully converted human embryonic stem ... future, replacement cartilage could be grown for transplantation ... problems, including sports injuries, new cartilage for people ... reconstructive surgery. , ,The research, to be ...
... scientists have developed a natural or rather biological pacemaker ... heart muscle cells. The newly developed pacemaker can fire ... the heart in a more physiological way., ,Two ... rise to the heart’s normal rhythm by stimulating other ...
... drugs is on the rise in England, accounting for more ... department each year. , ,The findings are based on ... a hospital in South West England. The doctor in charge ... for treatment with special reference to illegal drug abuse., ...
... previous claims new evidence shows the high fat, low carb ... Atkins (or simply the Atkins' diet) could damage the heart., ... and low // carbohydrates directly affected the heart's ability to ... and colleagues from the Cardiac Metabolism Research Group of Oxford ...
... know that heart disease is ranked as the first ... a new, simple test called dobutamine stress echocardiography that ... , ,The study has been conducted among a ... The study participants underwent a certain type of stress ...
Cached Medicine News:Health News:Partnership Between Diabetes India And Elsevier Announced 2Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Novel Biological Pacemaker Under Construction for Weak Hearts 2Health News:Heart damage a consequence of Atkins’ Die 2Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
... iQ200 Automated Urine Microscopy Analyzer (iQ200) ... (APR) software to classify urine particles ... results. The iQ200 eliminates most technologist ... particle images by automating specimen preparation, ...
... The iQ®200 Sprint Automated Urinalysis System ... fully automated system that performs complete urinalyses ... away. Designed for high volume laboratories or ... The iQ200 Sprint has a processing speed ...
StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
Medicine Products: